Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet
medical needs in some areas still exist. One of the main therapeutic approaches to alleviate …

Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19,
which has spread worldwide. No specific therapies/vaccines are yet available for the …

As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …

Abstract Objectives The Janus kinase (JAK) inhibitor baricitinib may block viral entry into
pneumocytes and prevent cytokine storm in patients with SARS-CoV-2 pneumonia. We …

The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and
tyrosine kinase 2 (TYK2), which are key components within the JAK–signal transducers and …

Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying
drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis …

Coronavirus disease 2019 (COVID-19) is a predominantly respiratory infectious disease
caused by novel coronavirus infection (SARS-CoV-2), respiratory failure is the main clinical …

In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-
related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious …

Cancer, a noncommunicable disease, is the leading cause of mortality worldwide and is
anticipated to rise by 75% in the next two decades, reaching approximately 25 million cases …

A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine
carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late …